On Jul. 1, 2020, InBios announced that it had received Emergency Use Authorization (EUA) from the FDA for its SCoV-2 Detect IgM ELISA kit, an in vitro diagnostic test for the qualitative detection of IgM antibodies to SARS-CoV-2, the virus that causes COVID-19, in human serum.

This marked the first EUA granted for an ELISA that specifically detects IgM antibodies to SARS-CoV-2 and underscores InBiosﾒ success in developing and bringing to market high-quality ELISA kits for emerging infectious diseases.